3Z and biotx.ai Forge Partnership to Advance ADHD Drug Development Using AI Modelling Reykjavik, Iceland and Berlin, Aug. 18, 2023 — Reykjavik-based drug discovery company, 3Z, and Germany/US-based causal AI firm, biotx.ai, have joined forces in a strategic partnership aimed at revolutionizing ADHD drug development. By leveraging advanced AI modelling techniques, the collaboration seeks to bridge...

3Z closes $2 million funding for preclinical development of novel ADHD and Insomnia therapeutics identified by 3Z´s zebrafish drug discovery platform Reykjavik, Jun. 20, 2022 – 3Z, a Reykjavik based drug discovery company is pleased toannounce the closure of a $2 million funding round led by seasoned investorsin pharmaceuticals and medical technology. The just closed...